---
figid: PMC12209467__41392_2025_2287_Fig2_HTML
figtitle: BMPR2 and TGFB signaling pathways in PH
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC12209467
filename: 41392_2025_2287_Fig2_HTML.jpg
figlink: /pmc/articles/PMC12209467/figure/F2/
number: F2
caption: BMPR2 and TGF-β signaling pathways in PH. a BMPR2 signaling pathway and targeted
  therapy in PH. Cathepsin L, hypoxia, MCT, and direct BMPR2 knockdown or mutations,
  inhibit BMPR2 signaling, which regulates GSDME, P53/PGC1-α, NOTCH, ERK, JNK, p38,
  PPARγ, miRNAs, STAT3, and SOD/ROS, leading to apoptosis or pyroptosis of PAECs and
  PMVECs in the early stage of PH, followed by hyperproliferation of PAECs, PMVECs
  and PASMCs. Additionally, EndMT, ECM remodeling (COL4 and COMP), contractile phenotype
  inhibition of PASMCs, and inflammation (IL-6, TNF, and HMGB1) are involved in PH
  progression. FK506, enzastaurin, follistatin, elafin, cathepsin l shRNA, seralutinib,
  AAV1.BMPR2, AAV1.SIN3a, isorhamnetin, GP130, DHEA, HJC0152, BMP9, RhBMP9 alleviate
  PH by upregulating or activating BMPR2 and its related pathways. b TGF-β signaling
  pathway and targeted therapy in PH. Su/Hx, galectin-3, Hypoxia, EVs derived from
  HIV-infected macrophages, IL-1β, H₂O₂, MCT and NBL1 upregulate TGF-β, which targets
  Smad2/3/4, or p38, decrease COL1, FN1, α-SMA, vimentin, OPN and PCNA, and increase
  Bcl-2, leading to ECM remodeling, proliferation, migration, anti-apoptotic, EndMT.
  Sotatercept, ginsenoside Rg1, aspirin, danshensu, berberine, IPA, pioglitazone,
  IN-1233, SB525334, and SD-208 mitigate PH by modulating TGF-β signaling. PASMC pulmonary
  artery smooth muscle cell, PAEC pulmonary artery endothelial cell, PMVEC pulmonary
  microvascular endothelial cell, PAF pulmonary artery fibroblast, BMPR2 bone morphogenetic
  protein receptor type 2, TGF-β transforming growth factor-β, FHIT fragile histidine
  triad, INHBA inhibin-β-A, ActA activin-A, GSDME gasdermin E, PGC-1α peroxisome proliferator-activated
  receptor gamma coactivator1-alpha, TFAM transcription factor A mitochondrial, Δψm
  mitochondrial membrane potential, ILK integrin-linked kinase, Smad small mothers
  against decapentaplegic, PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase
  3, ID1 inhibitor of differentiation 1, CRYAB a-crystallin B, nmMLCK non-muscle myosin
  light chain kinase, HMGA1 high mobility group at-hook 1, ERK extracellular signal-regulated
  kinase, JNK c-Jun N terminal kinase, MCT monocrotaline, NF-κB nuclear factor kappa
  B, CircGSAP circular RNA-γ-secretase-activating protein, PPARγ peroxisome proliferator-activated
  receptorγ, PFKP phosphofructokinase 1 platelet isoform, Drp1 dynamin-related protein
  1, HMGB1 high-mobility group box 1, TLR4 Toll-like receptor-4, COMP cartilage oligomeric
  matrix protein, SIN3a switch-independent 3a, DHEA dehydroepiandrosterone, HJC0152
  a STAT3 inhibitor, GP130 Glycoprotein 130, Su/Hx SU5416-hypoxia, GDF growth and
  differentiation factor, FN1 fibronectin1, OPN osteopontin, COL1 type I collagen,
  ET-1 endothelin-1, PCNA proliferating cell nuclear antigen, NBL1 neuroblastoma suppressor
  of tumorigenicity 1, EV extracellular vesicle, TNF tumor necrosis factor, LTB4 leukotrieneB4,
  IPA Inactivated Pseudomonas aeruginosa, 5-HT 5-hydroxytryptamine, 5-LO 5-lipoxygenase,
  EndMT endothelial-to-mesenchymaltransition, Caspase cysteinyl aspartate specific
  proteinase, miR microRNA, COL4 collagen type IV
papertitle: Signaling pathways and targeted therapy for pulmonary hypertension
reftext: Joseph Adu-Amankwaah, et al. Signal Transduct Target Ther. 2025;10(NA).
year: '2025'
doi: 10.1038/s41392-025-02287-8
journal_title: Signal Transduction and Targeted Therapy
journal_nlm_ta: Signal Transduct Target Ther
publisher_name: Nature Publishing Group
keywords: Cardiovascular diseases | Preclinical research | Inflammation | Cell biology
automl_pathway: 0.9343386
figid_alias: PMC12209467__F2
figtype: Figure
redirect_from: /figures/PMC12209467__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12209467__41392_2025_2287_Fig2_HTML.html
  '@type': Dataset
  description: BMPR2 and TGF-β signaling pathways in PH. a BMPR2 signaling pathway
    and targeted therapy in PH. Cathepsin L, hypoxia, MCT, and direct BMPR2 knockdown
    or mutations, inhibit BMPR2 signaling, which regulates GSDME, P53/PGC1-α, NOTCH,
    ERK, JNK, p38, PPARγ, miRNAs, STAT3, and SOD/ROS, leading to apoptosis or pyroptosis
    of PAECs and PMVECs in the early stage of PH, followed by hyperproliferation of
    PAECs, PMVECs and PASMCs. Additionally, EndMT, ECM remodeling (COL4 and COMP),
    contractile phenotype inhibition of PASMCs, and inflammation (IL-6, TNF, and HMGB1)
    are involved in PH progression. FK506, enzastaurin, follistatin, elafin, cathepsin
    l shRNA, seralutinib, AAV1.BMPR2, AAV1.SIN3a, isorhamnetin, GP130, DHEA, HJC0152,
    BMP9, RhBMP9 alleviate PH by upregulating or activating BMPR2 and its related
    pathways. b TGF-β signaling pathway and targeted therapy in PH. Su/Hx, galectin-3,
    Hypoxia, EVs derived from HIV-infected macrophages, IL-1β, H₂O₂, MCT and NBL1
    upregulate TGF-β, which targets Smad2/3/4, or p38, decrease COL1, FN1, α-SMA,
    vimentin, OPN and PCNA, and increase Bcl-2, leading to ECM remodeling, proliferation,
    migration, anti-apoptotic, EndMT. Sotatercept, ginsenoside Rg1, aspirin, danshensu,
    berberine, IPA, pioglitazone, IN-1233, SB525334, and SD-208 mitigate PH by modulating
    TGF-β signaling. PASMC pulmonary artery smooth muscle cell, PAEC pulmonary artery
    endothelial cell, PMVEC pulmonary microvascular endothelial cell, PAF pulmonary
    artery fibroblast, BMPR2 bone morphogenetic protein receptor type 2, TGF-β transforming
    growth factor-β, FHIT fragile histidine triad, INHBA inhibin-β-A, ActA activin-A,
    GSDME gasdermin E, PGC-1α peroxisome proliferator-activated receptor gamma coactivator1-alpha,
    TFAM transcription factor A mitochondrial, Δψm mitochondrial membrane potential,
    ILK integrin-linked kinase, Smad small mothers against decapentaplegic, PFKFB3
    6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, ID1 inhibitor of differentiation
    1, CRYAB a-crystallin B, nmMLCK non-muscle myosin light chain kinase, HMGA1 high
    mobility group at-hook 1, ERK extracellular signal-regulated kinase, JNK c-Jun
    N terminal kinase, MCT monocrotaline, NF-κB nuclear factor kappa B, CircGSAP circular
    RNA-γ-secretase-activating protein, PPARγ peroxisome proliferator-activated receptorγ,
    PFKP phosphofructokinase 1 platelet isoform, Drp1 dynamin-related protein 1, HMGB1
    high-mobility group box 1, TLR4 Toll-like receptor-4, COMP cartilage oligomeric
    matrix protein, SIN3a switch-independent 3a, DHEA dehydroepiandrosterone, HJC0152
    a STAT3 inhibitor, GP130 Glycoprotein 130, Su/Hx SU5416-hypoxia, GDF growth and
    differentiation factor, FN1 fibronectin1, OPN osteopontin, COL1 type I collagen,
    ET-1 endothelin-1, PCNA proliferating cell nuclear antigen, NBL1 neuroblastoma
    suppressor of tumorigenicity 1, EV extracellular vesicle, TNF tumor necrosis factor,
    LTB4 leukotrieneB4, IPA Inactivated Pseudomonas aeruginosa, 5-HT 5-hydroxytryptamine,
    5-LO 5-lipoxygenase, EndMT endothelial-to-mesenchymaltransition, Caspase cysteinyl
    aspartate specific proteinase, miR microRNA, COL4 collagen type IV
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - GDF2
  - CTSA
  - CTSB
  - CTSC
  - CTSD
  - CTSE
  - CTSF
  - CTSG
  - CTSH
  - CTSK
  - CTSL
  - CTSO
  - CTSS
  - CTSV
  - CTSW
  - CTSZ
  - BMPR2
  - HMGA1
  - EPHB2
  - MAPK1
  - MAPK3
  - CAV1
  - ACTA1
  - ID1
  - SMAD1
  - SMAD4
  - SMAD5
  - SMAD6
  - SMAD7
  - SMAD9
  - SMAD2
  - SMAD3
  - GSAP
  - TP53
  - TP63
  - TP73
  - PPARGC1A
  - CRYAB
  - FHIT
  - INHBA
  - GSDME
  - NOTCH1
  - COMP
  - PFKFB3
  - TNF
  - IL6
  - ILK
  - IL6ST
  - NM
  - LRPPRC
  - SOD1
  - SOD2
  - SOD3
  - SIN3A
  - STAT3
  - PFKP
  - COL4A1
  - COL4A2
  - COL4A3
  - COL4A4
  - COL4A5
  - COL4A6
  - IL1B
  - ALOX5
  - LTB4R
  - CRK
  - MAPK14
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - BCL2
  - TGFBR1
  - SUGCT
  - ETFA
  - NBL1
  - MICOS10-NBL1
  - IL1A
  - TWIST1
  - MAP3K3
  - ACVR2A
  - SLC16A1
  - MCAT
  - MCPH1
  - HTR2A
  - PCLAF
  - SPP1
  - PCNA
  - FN1
  - COL1A1
  - COL1A2
  - TGFB1
  - TGFB2
  - TGFB3
  - Isorhamnetin
  - DHEA
  - LTB4
  - 5-HT
  - ginsenoside RG1
  - PAF
---
